NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Omalizumab for treating previously treated chronic spontaneous urticaria

Please sign and return to:

Stuart Wood, Technology Appraisal Administrator
Email: TACommB@nice.org.uk
Fax: +44 (0)20 7061 9830
Post: NICE, 10 Spring Gardens, London, SW1A 2BU

I confirm that:

- I agree with the content of the statement submitted by the British Society for Allergy and Clinical Immunology (BSACI) and consequently I will not be submitting a personal statement.

Name: Dr Shuaib Nasser

Signed: .

Date: 29th July 2014